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CD11c
+ myeloid dendritic cells (DC) proposed to make use of this process, being captured by DC in mucosal tissues and delivered to the lymph node, which then becomes the principal site of virus replication. 3, 4 In humans, two main DC subsets are found: CD11c + myeloid DC (MDC) and CD11c -CD123 + plasmacytoid DC (PDC). MDC include Langerhans cells, dermal DC and interstitial DC, and are found in blood, skin and mucosal tissues and have been associated with HIV-1 capture and sexual transmission. PDC are located in blood and secondary lymphoid organs but they can be recruited to sites of inflammation. [5] [6] [7] The difference between MDC and PDC is furthermore manifested by differential expression of Toll-like receptors (TLRs) and secretion of different cytokines: MDC are known to secrete high levels of interleukin-12 (IL-12) whereas PDC are thought to play an important role in innate immune responses to different types of viruses by producing IFNα. [8] [9] [10] [11] [12] Several studies have shown that the numbers of both MDC and PDC are substantially reduced in the blood of patients infected with HIV-1 and that the DC are functionally impaired with respect to T cell proliferation and cytokine production. [13] [14] [15] [16] [17] [18] In addition, both types of DC have been shown to be susceptible to HIV-1 infection, and to be able to transmit the virus to CD4 + T cells in vitro. [19] [20] [21] In this study, we set out to compare the influence of differently matured MDC and PDC on HIV-1 infection of T cells. A large proportion of DC research is being performed with monocyte-derived DC, which represent the MDC subset. However, several differences have been described for these in vitro generated DC and MDC isolated from blood or skin. 22, 23 In addition, there is no in vitro PDC model available. Therefore, we 
Materials and methods
Isolation and culturing of DC
Peripheral blood mononuclear cells (PBMC) were isolated by density centrifugation on Lymphoprep (Nycomed, Torshov, Norway). Subsequently, MDC and PDC were isolated using magnetic bead isolation and AutoMACS (Miltenyi Biotec, Bergisch Gladbach, Germany). For MDC isolation, PBMC were depleted from B cells using anti-CD19 microbeads (Miltenyi Biotec) followed by positive selection with mouse-anti-human BDCA-1-PE and anti-PE-microbeads (Miltenyi Biotec). PDC isolation was performed with mouse-anti-human BDCA-4-PE and anti-PE microbeads (Miltenyi Biotec). Prior to incubation with CD19/BDCA-1/BDCA-4 antibodies the cells were pre-incubated with FcR-block for 5 min (Miltenyi Biotec). Culturing was done in Iscove's modified Dulbecco's medium (IMDM; Life Technologies Ltd., Paisley, United Kingdom) with gentamicin (86 µg/ml; Duchefa, Haarlem, The Netherlands) and 10% fetal clone serum (HyClone, Logan, Utah) at a density of 35×10 3 DC/well. The medium was supplemented with GM-CSF (500 U/ml; Schering-Plough, Uden, The Netherlands) or IL-3 (10 ng/ml; Strathmann Biotech AG, Hannover, Germany) for MDC and PDC respectively. Maturation of the DC was induced by culturing the cells for 24 hr with the following factors, provided alone or in combination as indicated in the text: maturation factors (MF; LPS (100 ng/ml, Difco, Detroit, MI, USA), IL-1β (10 ng/ml; Strathmann Biotec AG) and TNFα (50 ng/ml; Strathmann Biotec AG)), poly (I:C) (20 µg/ml; Sigma-Aldrich, St. Louis, MO), IFNγ (1000 U/ml; Strathmann Biotec AG), R-848 (2 µg/ml, Invivogen, San Diego, CA, USA) or fixed 
Virus stocks and T cells
C33A cervix carcinoma cells were transfected using calcium phosphate with 5 ng of the molecular clone of CXCR4-using HIV-1 LAI and CCR5-using JR-CSF. The virus containing supernatant was harvested 3 to 5 days post transfection, filtered and stored at -80°C. The concentration of virus was determined by CA-p24 ELISA. PM1 cells, which are susceptible to CXCR4-and CCR5-using HIV-1, 24 were maintained in Roswell Park Memorial Institute (RPMI) medium 1640 (Life Technologies), supplemented with 10% FCS, 2 mM sodium pyruvate, 10 mM HEPES, 2 mM L-glutamine, penicillin (100 U/ml) (Sigma-Aldrich) and streptomycin (100 µg/ml) (Invitrogen, Breda, The Netherlands 
Statistical analysis
Data were analysed for statistical significance (GraphPad InStat, Inc, San Diego, CA, USA) using ANOVA. A p value <0.05 was considered to be significant.
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Results
MDC enhance, whereas PDC inhibit HIV-1 infection of T cells
To The luciferase levels were comparable for all different maturation inducing compounds, meaning that they did not influence the induction of luciferase production by HIV-1 ( Fig.   1A and B, white bars). Please note that the scales of Fig 1A and Interestingly, the stimulating effect of MDC was not reproduced with the supernatant of MDC, but supernatant from PDC was sufficient to reduce luciferase levels ( Fig. 1A and B, gray bars). This result demonstrates that both DC subsets have opposing effects on HIV-1 infection of T cells, mediated through different mechanisms.
MDC do not stimulate HIV-1 infection through secreted factors
The results shown in Fig. 1A and B demonstrate that the stimulating effect of MDC is not mediated through a factor that is secreted during DC maturation. However, T cells can activate DC via CD40 ligand (CD40-L)-CD40 signaling, leading to increased expression of co-stimulatory molecules CD80/CD86 and cytokine release. 2 It is therefore still possible that the nature of the enhancing effect of MDC is a factor that is secreted after T cell engagement. To critically test this alternative explanation, we co-cultured differently matured MDC with a CD40L expressing cell line to mimic T cell encounter.
After 24 hr, the supernatant was collected and incubated with LuSIV cells and HIV-1, followed by luciferase measurement one day later. We found that MDC supernatant after CD40 ligation did not stimulate HIV-1 infection (Fig. 1C) . This demonstrates that in order to enhance HIV-1 infection, MDC must be present and that secreted factors do not play a role.
Differences in HIV-1 stimulation are not due to differences in HIV-1 capture
Interestingly, differently matured MDC vary in their ability to stimulate HIV-1 infection:
MDC matured with R-848, a stimulator of TLR7 and TLR8, 28 are most efficient in stimulation of HIV-1 infection in co-culture experiments without washing steps ( Fig. 1A and 1C). All mature MDC expressed comparable levels of maturation/activation markers CD83/86 (data not shown). Also in a transmission assay, in which the MDC were washed after HIV-1 incubation to remove unbound virus and other soluble compounds, the R-848 matured MDC are more efficient in HIV-1 stimulation ( Fig. 2A) . This shows that MDC stimulate HIV-1 infection of T cells through capture and transmission of the virus. To investigate whether differences in HIV-1 capture are responsible for this effect, differently matured MDC were incubated for 4 hr with HIV-1, followed by extensive washing to remove unbound virus. Viral capture was subsequently determined by lysis of the cells and CA-p24 ELISA. We found no differences in the amount of HIV-1 capture (Fig. 2B) , showing that the increased transmission by R-848 matured MDC must act at a later step.
ICAM-1 expression is required for MDC-mediated transmission
We have previously shown that the interaction between the integrins ICAM-1 on DC and LFA-1 on T cells is crucial for HIV-1 transmission. Mature monocyte-derived DC that express higher levels of ICAM-1 have an enhanced capacity to transmit HIV-1, 29 and transmission to LFA-1 negative T cells is impaired. 30 The ICAM-1−LFA-1 interaction plays a key role in the initiation of immune responses by strengthening the adhesion between DC and T cells at the immunological synapse. 31, 32 To explore the possibility of increased integrin expression on R-848 matured MDC, differently matured MDC were analysed by FACS (Fig. 3A-D) . MDC matured by R-848 do indeed express more ICAM-1, but MDC matured with IFNγ/MF express even higher levels (Fig. 3A) . These data imply that there must be additional reasons for the superiority of R-848 matured MDC.
LFA-1 can also interact with ICAM-2 or -3, 33, 34 but no expression of ICAM-2 was found on MDC, whereas ICAM-3 was not differently expressed on matured MDC, suggesting that the latter is not responsible for the enhanced transmission by R-848 MDC ( Fig. 3B and C). LFA-1 is expressed on T cells, but can also be found on DC. 35 However, we found no differences in LFA-1 expression either (Fig. 3D) . To confirm our previous work on the importance of the ICAM-1−LFA-1 interaction, blocking antibodies were used to (Fig. 3E) . These results show that ICAM-1 is still a prerequisite for DC-mediated HIV-1 transmission to T cells, but that there must be another factor responsible for the increased transmission by R-848 matured MDC.
PDC supernatant inhibits replication of both CXCR4-and CCR5-using HIV-1
PDC supernatant inhibits HIV-1 in the single-cycle replication assay (Fig. 1B) . We next investigated whether this supernatant could inhibit HIV-1 over an extended period of time during a spreading infection in T cells. We therefore infected the PM1 T cell line with HIV-1 in the presence of supernatant from SAC-stimulated PDC. HIV-1 replication was followed by measuring CA-p24 accumulation in the supernatant by ELISA. Both CXCR4-and CCR5-using HIV-1 were significantly inhibited 10-fold by PDC supernatant in this spreading assay ( Fig. 4A; p<0.01) , and the supernatant could be diluted 10 times before it lost its inhibitory properties (Fig. 4B) . This spreading assay however could underestimate the actual inhibitory capacity of the supernatant, because the inhibitor is gradually lost due to possible degradation and necessary refreshment of the medium.
We therefore tested the supernatant dilutions also in the single-cycle replication assay, and found that the supernatant could be diluted 100 times without losing its inhibitory properties (Fig. 4C) . 12,36-38 With ELISA, we found that SAC and poly(I:C) stimulated PDC secrete high levels of IFNα (3925 ± 75 and 4295 ± 104 pg/ml respectively). We therefore tried to counteract the inhibitory effect of PDC supernatant using well-described blocking antibodies against type I IFNs 27 . Both PM1 T cells and PDC supernatant were preincubated with the antibodies before HIV-1 infection, followed by co-culture for several days during which HIV-1 replication was monitored by measuring CA-p24 accumulation in the supernatant. Neutralization of type I IFNs partially restored virus replication, as shown for the day 5 sample of the replication curve (Fig. 5 ). Even at twice the optimal antibody concentration, we found no further restoration of HIV-1 replication, suggesting that type I IFNs are only partially responsible for the inhibitory effect of PDC supernatant on HIV-1 replication.
PDC secrete an additional inhibitory factor of <3 kDa
To confirm the presence of an additional inhibitory factor in PDC supernatant, a size fractionation of the supernatant was performed using centrifugal filters. The resulting fractions of <3, 3-10, 10-30, 30-100 and >100 kDa were subsequently tested for their capacity to inhibit HIV-1 infection in the single-cycle replication assay with LuSIV cells.
The <3 kDa, 30-100 and >100 kDa fractions inhibited HIV-1 infection significantly, whereas the fractions between 3 and 30 kDa did not (black bars Fig. 6A ). All fractions were tested for the presence of IFNα by ELISA (grey bars Fig. 6A) . The 30-100 kDa fractions contained high levels of IFNα, as well as the >100 kDa fraction, probably because this molecule (±20 kDa) is present as dimers 39 or complexed with other molecules or serum components. More importantly, the <3 kDa fraction contained no IFNα (Fig 6A) , and addition of neutralizing antibodies against type I IFNs did not reverse the inhibitory properties of this fraction (Fig. 6B) . A full restoration of HIV-1 infectivity was obtained when the antibodies were used to neutralize the type I IFNs in the 30-100 kDa fraction, confirming the functioning of the antibodies (Fig 6B) . Both IFNα and the small molecule inhibitor are heat sensitive, since incubating the respective fractions at 50, 75 or 100°C resulted in loss of inhibitory properties (Fig. 7) . This suggests that the inhibitory factor is a small polypeptide.
Discussion
In the present study, we compared differently matured MDC and PDC from peripheral blood for their influence on HIV-1 infection of T cells. Opposing effects were scored:
MDC strongly promote HIV-1 infection, and PDC severely inhibit HIV-1 replication. The former finding has been described before 40 and we extended these findings here by
showing that soluble factors secreted during MDC maturation or following T cell encounter do not influence this process. To the best of our knowledge, no comparison has been made of differently matured blood MDC and their ability to transmit HIV-1. We have previously shown that differently matured monocyte-derived DC have different transmission efficiencies, which correlates with differences in ICAM-1 expression. 29 Here we show that the same rule did not apply to blood MDC: MDC matured with R-848 enhance HIV-1 infection twice as efficient as MDC matured with SAC, IFNγ/MF or poly (I:C), which does not perfectly correlate with ICAM-1 expression. Although we could confirm that ICAM-1 is a prerequisite for MDC-mediated HIV-1 transmission (Fig 3E) , an additional factor seems to contribute to the increased HIV-1 transmission by R-848 matured MDC. This factor is not another integrin like ICAM-2, ICAM-3 or LFA-1, and the amount of viral capture by R-848 MDC was comparable to that of immature MDC or IFNγ/MF-matured MDC. One possible explanation is that HIV-1 is degraded to a smaller extent after capture by R-848 MDC. Significant viral degradation occurs after viral capture, 41 but a proportion of the virus survives by residing in a non-lysosomal compartment followed by transmission to T cells. 42, 43 Maturation of MDC with R-848 could possibly change the balance between degradation and survival of HIV-1.
Consequently, R-848 matured MDC could direct HIV-1 more efficiently or in larger amounts towards the infectious synapse. 43, 44 More research on the differences between 48 but we now demonstrate that PDC secrete at least one additional inhibitory factor that is smaller than 3 kDa. This factor is heat-sensitive, but remains to be identified. Some candidate inhibitors can be excluded. The group of chemokines that block the co-receptor, thereby preventing HIV-1 entry into T cells, 49 are too large.
Furthermore, PDC do not secrete the SDF-1 ligand for CXCR4 and very little of the RANTES/MIP-1α/β ligands for CCR5. 50 Indeed, the PDC supernatant inhibits CXCR4-and CCR5-using HIV-1 infection to the same extent (Fig. 4A) .
Another group of possible candidates are antimicrobial peptides. These small peptides (1-5 kDa) are secreted by different cell types and are active against a broad range of bacteria, fungi and viruses. 51, 52 With respect to HIV-1, three inhibitory mechanisms of antimicrobial peptides have been described: direct virolysis, inhibition of For personal use only. on November 12, 2017. by guest www.bloodjournal.org From transcription from the LTR promoter and block of entry by binding to cell surface molecules. [53] [54] [55] [56] The production of antimicrobial peptides by PDC has not been studied extensively. One study reported small amounts of intracellular human β-defensin 1 (hBD-1) in PDC from some donors. 57 Another group showed that monocyte-derived MDC harbor low amounts of mRNA for hBD-1 and hBD-2. 58 hBD-1, and hBD-2 in particular, have been shown to inhibit HIV-1 replication by an unidentified mechanism. 59 In our study, we found that PDC of some donors express marginal amounts of mRNA for hBD-1 and hBD-2, and that no mRNA for another antimicrobial peptide, LL-37, was detected (S. J. P. Bogaards & P. H. Nibbering, unpublished results). For this reason, it is not very likely that hBD-1 or hBD-2 is the additional HIV-1 inhibitor in PDC supernatant.
It cannot be excluded that other antimicrobial peptides are responsible for the inhibition.
It would be of interest to perform a further search for this inhibitor and investigate whether the factor inhibits other viruses as well. Not only will this broaden our knowledge on the antiviral response of PDC, but it could also create novel therapeutic options.
The differential impact of MDC and PDC on HIV-1 infection may reflect the different location and function of these cells in the human body. MDC constantly sample the outside milieu to detect pathogens and form a direct link between innate and adaptive immunity. 2 It is known for several years that they stimulate HIV-1 infection, 40 and it has been proposed that they transmit the virus to T cells following migration to secondary lymphoid organs. 60 Their role in HIV-1 infection is therefore better understood than the role of PDC. It is not very likely PDC are similarly involved in HIV-1 capture in mucosal tissues. PDC are not located in high amounts at sites of pathogen entry, they do not capture, endocytose and process antigens as effectively as MDC, and their role in T cell proliferation is less pronounced. 11 In contrast, PDC are involved in the innate immune response against many viruses, including HSV-1 and -2, influenza, VSV and HIV-1. 11 Their role in HIV-1 infection may be to control the virus in order to delay disease progression. The numbers of both MDC and PDC in blood of HIV-1 infected patients are reduced. 13, 14, 16, 18 Since both types of DC can be infected by HIV-1, 19, 20, 61 this reduction can be the result of depletion. Alternatively, they may have relocated to secondary lymphoid tissue as a consequence of HIV-1 infection. 62, 63 Both types of DC isolated from HIV-1 patients were reported to be functionally impaired with respect to T cell stimulation and cytokine production. 
